BIOCORP Reports H1 2021 Results - Seite 3
The 2021 half-year financial report is available on the Company's website.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected
medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with
diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015
(FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20210926005004/en/